FibroGen Performance
| FGENDelisted Stock | USD 9.22 0.29 3.05% |
The firm shows a Beta (market volatility) of 0.23, which means not very significant fluctuations relative to the market. As returns on the market increase, FibroGen's returns are expected to increase less than the market. However, during the bear market, the loss of holding FibroGen is expected to be smaller as well. At this point, FibroGen has a negative expected return of -0.29%. Please make sure to confirm FibroGen's jensen alpha, accumulation distribution, relative strength index, as well as the relationship between the value at risk and day typical price , to decide if FibroGen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days FibroGen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 113.7 M | |
| Total Cashflows From Investing Activities | 126 M |
FibroGen |
FibroGen Relative Risk vs. Return Landscape
If you would invest 1,100 in FibroGen on November 6, 2025 and sell it today you would lose (178.00) from holding FibroGen or give up 16.18% of portfolio value over 90 days. FibroGen is currently does not generate positive expected returns and assumes 4.5862% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than FibroGen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
FibroGen Target Price Odds to finish over Current Price
The tendency of FibroGen Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 9.22 | 90 days | 9.22 | about 63.39 |
Based on a normal probability distribution, the odds of FibroGen to move above the current price in 90 days from now is about 63.39 (This FibroGen probability density function shows the probability of FibroGen Stock to fall within a particular range of prices over 90 days) .
FibroGen Price Density |
| Price |
Predictive Modules for FibroGen
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as FibroGen. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of FibroGen's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
FibroGen Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. FibroGen is not an exception. The market had few large corrections towards the FibroGen's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold FibroGen, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of FibroGen within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.22 | |
β | Beta against Dow Jones | 0.23 | |
σ | Overall volatility | 1.14 | |
Ir | Information ratio | -0.06 |
FibroGen Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of FibroGen for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for FibroGen can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| FibroGen is now traded under the symbol KYNB. Please update your portfolios or report it if you believe this is an error. Report It! | |
| FibroGen is not yet fully synchronised with the market data | |
| FibroGen generated a negative expected return over the last 90 days | |
| FibroGen has high historical volatility and very poor performance | |
| FibroGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 29.62 M. Net Loss for the year was (47.58 M) with loss before overhead, payroll, taxes, and interest of (30.35 M). | |
| FibroGen currently holds about 438.13 M in cash with (138 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67. | |
| Latest headline from news.google.com: FibroGen Faces Option Delistings as of January 8th - GuruFocus |
FibroGen Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of FibroGen Stock often depends not only on the future outlook of the current and potential FibroGen's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. FibroGen's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 100 M | |
| Cash And Short Term Investments | 50.5 M |
FibroGen Fundamentals Growth
FibroGen Stock prices reflect investors' perceptions of the future prospects and financial health of FibroGen, and FibroGen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FibroGen Stock performance.
| Return On Equity | -10.16 | |||
| Return On Asset | -0.18 | |||
| Profit Margin | 25.99 % | |||
| Operating Margin | (4.99) % | |||
| Current Valuation | 86.86 M | |||
| Shares Outstanding | 4.05 M | |||
| Price To Earning | 97.67 X | |||
| Price To Book | 53.83 X | |||
| Price To Sales | 4.40 X | |||
| Revenue | 29.62 M | |||
| EBITDA | (142.43 M) | |||
| Cash And Equivalents | 438.13 M | |||
| Cash Per Share | 4.67 X | |||
| Total Debt | 90.17 M | |||
| Debt To Equity | 0.89 % | |||
| Book Value Per Share | (4.21) X | |||
| Cash Flow From Operations | (138 M) | |||
| Earnings Per Share | (12.85) X | |||
| Total Asset | 214.53 M | |||
| Retained Earnings | (1.89 B) | |||
| Current Asset | 200.56 M | |||
| Current Liabilities | 67.18 M | |||
About FibroGen Performance
By examining FibroGen's fundamental ratios, stakeholders can obtain critical insights into FibroGen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that FibroGen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Fibrogen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 566 people.Things to note about FibroGen performance evaluation
Checking the ongoing alerts about FibroGen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for FibroGen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| FibroGen is now traded under the symbol KYNB. Please update your portfolios or report it if you believe this is an error. Report It! | |
| FibroGen is not yet fully synchronised with the market data | |
| FibroGen generated a negative expected return over the last 90 days | |
| FibroGen has high historical volatility and very poor performance | |
| FibroGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 29.62 M. Net Loss for the year was (47.58 M) with loss before overhead, payroll, taxes, and interest of (30.35 M). | |
| FibroGen currently holds about 438.13 M in cash with (138 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67. | |
| Latest headline from news.google.com: FibroGen Faces Option Delistings as of January 8th - GuruFocus |
- Analyzing FibroGen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether FibroGen's stock is overvalued or undervalued compared to its peers.
- Examining FibroGen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating FibroGen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of FibroGen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of FibroGen's stock. These opinions can provide insight into FibroGen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in FibroGen Stock
If you are still planning to invest in FibroGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FibroGen's history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities |